Lunai Bioworks asks Nasdaq to suspend trading in its common stock
Lunai Bioworks asked Nasdaq on October 9, 2026 to immediately suspend trading in its stock, citing trading records from its pending Delaware litigation that it says raise serious questions about whether trading has occurred in a fair and orderly market. Nasdaq has not decided, and the request itself does not halt trading, so shareholders face uncertainty about whether trading will continue.
Key points
- Request submitted to Nasdaq on October 9, 2026, asking for an immediate trading suspension while Nasdaq, FINRA and other authorities review trading records
- Records cited include substantial short selling, locate deficiencies and concentrated failures to deliver, based on court-ordered discovery in Lunai Bioworks, Inc. v. Seven Points Capital LLC et al.
- As of the filing, Nasdaq had not responded, and the company cannot predict if or when it will act; allegations have not been adjudicated
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.